Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $36.0 million.

  • Kyntra Bio's Total Current Liabilities fell 8111.95% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.0 million, marking a year-over-year decrease of 8111.95%. This contributed to the annual value of $133.3 million for FY2024, which is 3875.72% down from last year.
  • As of Q3 2025, Kyntra Bio's Total Current Liabilities stood at $36.0 million, which was down 8111.95% from $155.9 million recorded in Q2 2025.
  • Kyntra Bio's Total Current Liabilities' 5-year high stood at $273.6 million during Q4 2022, with a 5-year trough of $36.0 million in Q3 2025.
  • Moreover, its 5-year median value for Total Current Liabilities was $209.3 million (2021), whereas its average is $193.0 million.
  • As far as peak fluctuations go, Kyntra Bio's Total Current Liabilities surged by 20006.57% in 2021, and later plummeted by 8111.95% in 2025.
  • Over the past 5 years, Kyntra Bio's Total Current Liabilities (Quarter) stood at $225.5 million in 2021, then rose by 21.32% to $273.6 million in 2022, then decreased by 20.43% to $217.7 million in 2023, then plummeted by 38.76% to $133.3 million in 2024, then crashed by 73.01% to $36.0 million in 2025.
  • Its Total Current Liabilities stands at $36.0 million for Q3 2025, versus $155.9 million for Q2 2025 and $73.4 million for Q1 2025.